
Pfizer Inc
NYSE:PFE

Intrinsic Value
Pfizer Inc. is a research-based global biopharmaceutical company. [ Read More ]
The intrinsic value of one
PFE
stock under the Base Case scenario is
42.49
USD.
Compared to the current market price of 33.1 USD,
Pfizer Inc
is
Undervalued by 22%.


Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up
to access Pfizer Inc's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
DCF Value
Discounted Cash Flow
Fundamental Analysis
Balance Sheet Decomposition
Pfizer Inc
Current Assets | 50.1B |
Cash & Short-Term Investments | 20B |
Receivables | 15.4B |
Other Current Assets | 14.7B |
Non-Current Assets | 146B |
Long-Term Investments | 14.7B |
PP&E | 17.1B |
Intangibles | 93.5B |
Other Non-Current Assets | 20.3B |
Current Liabilities | 36.6B |
Accounts Payable | 6.1B |
Accrued Liabilities | 2.3B |
Short-Term Debt | 621m |
Other Current Liabilities | 27.5B |
Non-Current Liabilities | 58.1B |
Long-Term Debt | 31.7B |
Other Non-Current Liabilities | 26.4B |
PFE Profitability Score
Profitability Due Diligence
Pfizer Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

Score
Pfizer Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
PFE Solvency Score
Solvency Due Diligence
Pfizer Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Score
Pfizer Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PFE Price Targets Summary
Pfizer Inc
According to Wall Street analysts, the average 1-year price target for
PFE
is 44.97 USD
with a low forecast of 32.32 USD and a high forecast of 78.75 USD.
Ownership
PFE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PFE Price
Pfizer Inc
Average Annual Return | 13.9% |
Standard Deviation of Annual Returns | 30.94% |
Max Drawdown | -45% |
Market Capitalization | 187B USD |
Shares Outstanding | 5 727 000 000 |
Percentage of Shares Shorted | 0.89% |
PFE News
Last Video News
Pfizer Inc
Last Important Events
Pfizer Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Pfizer Inc
Company Profile


Country
Industry
Market Cap
Dividend Yield
Description
Pfizer Inc. is a research-based global biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 79,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The firm offers therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator in development for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. The firm works across markets to develop wellness, prevention, treatments and cures. The company collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. The firm's medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness.
Contact
IPO
Employees
Officers
The intrinsic value of one
PFE
stock under the Base Case scenario is
42.49
USD.
Compared to the current market price of 33.1 USD,
Pfizer Inc
is
Undervalued by 22%.